DRUG NAME: Ampicillin + Sulbactam

• Parenteral doses are expressed as the total combined weight (ampicillin + sulbactam) with individual components in parentheses: e.g., “1.5 g (Ampicillin 1 g + Sulbactam 0.5 g).”
• When high-dose sulbactam regimens are discussed (for Acinetobacter infections), doses are specified in terms of the sulbactam component.
• Oral doses are expressed as sultamicillin weight.

---

Therapeutic Class:

---

Subclass:

---

Schedule (India):

---

Route(s)

• Intravenous (IV) — slow IV injection or IV infusion (primary route; preferred for moderate-severe infections)
• Intramuscular (IM) — deep IM injection (acceptable alternative when IV access is unavailable; suitable for outpatient parenteral antibiotic therapy [OPAT])
• Oral — as Sultamicillin tablets (for step-down therapy from IV/IM, or outpatient management of mild-moderate infections)

---

Biosimilar Status:

---

Formulations Available in India

A. Parenteral Formulations (Ampicillin + Sulbactam — 2:1 Ratio)

B. Oral Formulation — Sultamicillin

C. Clinically Relevant Fixed-Dose Combinations (FDCs)

• Ampicillin + Sulbactam + Probenecid: Not commonly available or used in Indian market.
• No other clinically relevant FDCs containing ampicillin-sulbactam are in standard Indian practice.

D. Related Formulation Note — Sulbactam Alone

---

PHARMACOKINETICS

• Ampicillin is a substrate of:
  • PepT1 (SLC15A1) — intestinal peptide transporter (for oral absorption, though less relevant for sultamicillin which is absorbed as the ester)
  • OAT1 (SLC22A6) and OAT3 (SLC22A8) — renal organic anion transporters mediating active tubular secretion
  • MRP2 (ABCC2) — contributes to minor biliary excretion
• Ampicillin is not a clinically significant substrate, inhibitor, or inducer of P-glycoprotein (P-gp), OATP1B1/1B3, BCRP, OCT2, or MATE1/2.
• Sulbactam — renal elimination via OAT1/OAT3. No clinically significant CYP or P-gp interactions identified.
• Neither component is a significant CYP450 substrate, inhibitor, or inducer.

---

---

---

---

ADULT INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

1. Does this patient truly need parenteral antibiotic therapy? (Can oral amoxicillin-clavulanate suffice?)
2. Is the spectrum of ampicillin-sulbactam appropriate for the suspected pathogen(s)?
3. Has the patient been assessed for IV-to-oral step-down at 48–72 hours?

• Gram-positive:Streptococcus spp. (including pneumococcus), Staphylococcus aureus (MSSA — NOT MRSA), Enterococcus faecalis (NOT E. faecium)
• Gram-negative:H. influenzae, M. catarrhalis, E. coli, Klebsiella spp., Proteus mirabilis (beta-lactamase producers — susceptible strains only), Neisseria spp. ⛔ Does NOT reliably cover ESBL-producing Enterobacterales — and ESBL prevalence in Indian hospitals is extremely high (40–70% in many centres). This limits the reliability of ampicillin-sulbactam as empiric therapy for nosocomial gram-negative infections in India unless culture-guided.
• Anaerobes:Bacteroides fragilis (most strains), Prevotella, Peptostreptococcus, Fusobacterium, Clostridium spp. (NOT C. difficile). Good anaerobic coverage is a strength of this combination.
• Acinetobacter baumannii: Sulbactam has intrinsic activity (see Part 1). However, MICs have risen significantly among Indian nosocomial A. baumannii isolates; susceptibility must be confirmed by culture.
• ⛔ NOT active against: MRSA, Pseudomonas aeruginosa, ESBL-producing organisms, Enterococcus faecium, Stenotrophomonas, Legionella, Mycoplasma, Chlamydophila, mycobacteria.

---

• Max per dose: 3 g (Ampicillin 2 g + Sulbactam 1 g)
• Max per day: 12 g (Ampicillin 8 g + Sulbactam 4 g)
• Starting dose: Full therapeutic dose from first administration (no titration for antibiotics)
• Titration: Not applicable

• Max per dose: 750 mg sultamicillin
• Max per day: 1500 mg sultamicillin (= approximately Ampicillin 880 mg + Sulbactam 590 mg/day)
• ℹ️ Oral sultamicillin delivers substantially lower ampicillin doses than parenteral therapy. For this reason, oral sultamicillin is appropriate only for mild infections or step-down after clinical response on IV therapy. For most oral step-down situations in Indian practice, switching to oral amoxicillin-clavulanate (which delivers higher amoxicillin doses) is preferred and more widely practiced.

---

---

1. When to prefer this drug over alternatives: Ampicillin-sulbactam IV is recommended as one of the first-line empiric options for mild-moderate, community-acquired intra-abdominal infections (IAIs) per ICMR Antimicrobial Treatment Guidelines 2019 and API Textbook. It provides adequate coverage against enteric gram-negatives (non-ESBL), streptococci, enterococci (E. faecalis), and anaerobes (Bacteroides fragilis) — the typical polymicrobial flora of community-acquired IAIs. Its enterococcal coverage is a specific advantage over many cephalosporins in mixed peritoneal infections. The API Textbook of Medicine recommends ampicillin-sulbactam as a single-agent option for non-severe, community-acquired IAIs, an approach also supported by the Surgical Infections Society (SIS) guidelines (adapted for Indian practice).
2. When NOT to use: ⛔ NOT adequate for hospital-acquired (nosocomial) IAIs, post-operative peritonitis, tertiary peritonitis, or infections with suspected ESBL-producing organisms (prevalence >40–70% among nosocomial E. coli and Klebsiella in most Indian hospitals). For these, use piperacillin-tazobactam, carbapenems, or cephalosporin + metronidazole per institutional antibiogram. Also ⛔ NOT adequate if Pseudomonas is suspected (no anti-pseudomonal activity).
3. NLEM India status: ✅ Ampicillin is included in NLEM India 2022 (Injection 250 mg, 500 mg). The combination with sulbactam as such is not separately listed in NLEM 2022 but ampicillin and sulbactam are used together under standard clinical practice. Sulbactam injection is available and widely used but its NLEM listing is as a combination component.
4. Time to expected clinical response: Clinical improvement (defervescence, reduction in abdominal pain/tenderness, improving bowel function) expected within 48–72 hours post-source-control. If no improvement by 72 hours, reassess.
5. Treatment failure criteria: No improvement at 72 hours (persistent fever, worsening abdominal signs, rising WBC/CRP) → reassess source control adequacy (repeat imaging — CT abdomen). Consider: inadequate drainage, missed collection, resistant organism, tertiary peritonitis. Obtain repeat cultures. Broaden coverage (piperacillin-tazobactam or carbapenem).
6. Mandatory baseline investigations:
   • MANDATORY: Allergy history (penicillin allergy check). CBC, renal function, blood cultures ×2.
   • RECOMMENDED: LFTs, CRP/procalcitonin, lactate (if sepsis suspected). Imaging (USG/CT abdomen) for source localisation. Intra-operative/aspirate culture and sensitivity.
7. Specialist initiation: Surgeon involvement mandatory for source control. Physician/ID specialist for antibiotic guidance in complicated cases. Primary care initiation not appropriate for IAIs (hospitalised patients).
8. Indian guideline source: API Textbook of Medicine (Intra-Abdominal Infections chapter); ICMR Antimicrobial Treatment Guidelines 2019; AIIMS Empiric Antibiotic Policy.
9. Key safety warning: ⚠️ Source control is paramount. Antibiotics alone without adequate surgical source control (drainage, appendectomy, cholecystectomy, repair of perforation) are insufficient for most IAIs. Delays in source control significantly increase mortality regardless of antibiotic choice.
10. Dose adjustment: Renal impairment (see Renal Adjustment). Elderly — dose per renal function.

---

1. When to prefer: Ampicillin-sulbactam is preferred over amoxicillin-clavulanate IV for obstetric infections because: (a) it is the standard parenteral aminopenicillin-BLI combination used in Indian hospital practice for this indication; (b) provides good enterococcal coverage (E. faecalis — common in postpartum infections); © excellent anaerobic coverage; (d) good uterine/adnexal tissue penetration. API Textbook and FOGSI guidelines support its use.
2. When NOT to use: ⛔ If MRSA is suspected (post-surgical wound infection with MRSA risk factors) — add vancomycin or use clindamycin-based regimen. ⛔ If nosocomial gram-negative infection suspected post-prolonged hospitalisation — ESBL coverage needed (piperacillin-tazobactam or carbapenem).
3. NLEM India: Ampicillin is ✅ NLEM. The combination as an obstetric antibiotic is standard practice.
4. Time to response: Defervescence within 48–72 hours. Reduction in uterine tenderness, lochia normalisation.
5. Treatment failure: If febrile at 72 hours → rule out pelvic abscess, wound infection (post-CS), septic pelvic thrombophlebitis, retained products. Imaging (pelvic USG/CT). Switch to broader coverage ± anticoagulation if septic pelvic thrombophlebitis suspected.
6. Baseline investigations: MANDATORY: Allergy history, CBC, blood cultures (before starting IV antibiotics), renal function. RECOMMENDED: Endometrial/wound cultures if feasible, CRP, high vaginal swab for PID.
7. Specialist initiation: Obstetrician/gynaecologist involvement mandatory. Not for primary care initiation.
8. Indian guideline: FOGSI Guidelines on Obstetric Infections; API Textbook (Obstetric and Gynaecological Infections); AIIMS Obstetric Antibiotic Protocol.
9. Key safety warning: ⚠️ In obstetric infections, always assess for sepsis (qSOFA/SOFA). Post-partum sepsis remains a leading cause of maternal mortality in India. Delayed initiation of appropriate antibiotics in obstetric sepsis is associated with significant mortality increase — administer the first dose within 1 hour of recognising sepsis.
10. Dose adjustment: Renal impairment — see Renal Adjustment. Pregnancy PK (increased clearance) — standard doses generally adequate; consider higher frequency (q6h rather than q8h) for severe infections.

---

• Preferred when polymicrobial infection is suspected (diabetic patients, lower extremity with venous stasis, post-traumatic wounds).
• If simple cellulitis from Group A Streptococcus alone is suspected, narrow-spectrum agents (ampicillin alone, or cefazolin) are sufficient.
• ⛔ Does NOT cover MRSA. If purulent SSTI (abscess with surrounding cellulitis) or MRSA risk: add vancomycin/linezolid or use clindamycin.

• Ampicillin-sulbactam IV/IM is the parenteral drug of choice for moderate-severe bite wound infections requiring hospitalisation. Provides the same polymicrobial coverage as amoxicillin-clavulanate (oral drug of choice) — Pasteurella, Eikenella, oral anaerobes, streptococci, staphylococci.
• ⚠️ India-specific: Always concurrently assess and administer anti-rabies prophylaxis per National Rabies Control Programme guidelines. Antibiotic treats bacterial infection; it has NO activity against rabies virus.
• Step down to oral amoxicillin-clavulanate once able to take oral medications.

• Appropriate for mild-moderate diabetic foot infections (IDSA/IWGDF classification: PEDIS Grade 2–3).
• ⚠️ For moderate-severe or limb-threatening infections: consider broader coverage (piperacillin-tazobactam or carbapenem) based on culture data. ESBL prevalence in diabetic foot wounds in India is high.
• Always: obtain wound culture, assess for osteomyelitis (probe-to-bone test, X-ray, MRI if available), optimise glycaemic control.

1. NLEM India: Ampicillin ✅ NLEM.
2. Time to response: 48–72 hours. Mark the extent of cellulitis with ink to track progression.
3. Treatment failure: No improvement at 72 hours → consider MRSA, deeper infection (necrotising fasciitis, osteomyelitis), abscess requiring drainage, or alternative diagnosis. Obtain wound culture. Imaging for deep collections.
4. Baseline investigations: MANDATORY: Allergy history. RECOMMENDED: Wound swab for culture, blood glucose (diabetes), renal function, blood cultures if systemically unwell.
5. Specialist initiation: Primary care can initiate for moderate SSTI. Surgical referral for: deep abscesses, debridement, suspected necrotising fasciitis, hand infections.
6. Indian guideline: API Textbook; ICMR AMR Treatment Guidelines 2019.
7. Key safety warning: ⛔ Necrotising fasciitis is a surgical emergency — do NOT rely on antibiotics alone. Clinical features: pain out of proportion, crepitus, rapid progression, systemic toxicity. Immediate surgical exploration and debridement + broad-spectrum IV antibiotics.

---

1. When to prefer: Ampicillin-sulbactam IV is a recommended first-line empiric IV antibiotic for hospitalised, non-ICU CAP (CURB-65 score 2, or hospitalised for other reasons) per ICMR Antimicrobial Treatment Guidelines and API Textbook. Provides coverage against pneumococcus (penicillin-susceptible and intermediate), H. influenzae, M. catarrhalis, oral anaerobes (aspiration), and S. aureus (MSSA). Must be combined with a macrolide or doxycycline for atypical organism coverage.
2. 💡 The API Textbook and joint ICS-NCDC Guidelines for CAP list ampicillin-sulbactam as one of the first-line IV options for hospitalised non-severe CAP, alongside IV amoxicillin-clavulanate and ceftriaxone. AIIMS empiric antibiotic policy also includes ampicillin-sulbactam in this role.
3. When NOT to use: ⛔ NOT for severe CAP (CURB-65 ≥3, ICU admission) as monotherapy — requires broader coverage (piperacillin-tazobactam or cephalosporin + macrolide/fluoroquinolone). ⛔ Does NOT cover atypical pathogens as monotherapy (Mycoplasma, Legionella, Chlamydophila) — always combine with macrolide or doxycycline. ⛔ If aspiration pneumonia with known MRSA risk — add vancomycin.
4. NLEM India: Ampicillin ✅ NLEM.
5. Time to response: Defervescence, reduced cough, improved oxygenation within 48–72 hours. CRP should decline by >50% at day 3–4.
6. Treatment failure at 72 hours: Reassess: rule out complications (empyema, lung abscess), drug-resistant organism, atypical pathogen, non-infectious mimic (malignancy, TB, organising pneumonia). Obtain sputum culture, blood cultures. Consider broadening coverage.
   ⚠️ India-specific: Always consider tuberculosis in non-resolving pneumonia, especially with risk factors, cavitation, weight loss, or epidemiological exposure. Obtain sputum AFB and GeneXpert.
7. Baseline investigations: MANDATORY: Chest X-ray, SpO₂, allergy history. RECOMMENDED: CBC, CRP/procalcitonin, renal function, blood cultures ×2, sputum Gram stain and culture (if obtainable), ABG (if SpO₂ <92%).
8. Specialist initiation: Physician/internist for hospitalised CAP. Not typically a primary care parenteral prescription.
9. Indian guideline: API Textbook (CAP chapter); ICMR Antimicrobial Treatment Guidelines 2019; Joint ICS-NCDC Guidelines for CAP; AIIMS Empiric Antibiotic Policy.
10. Key safety warning: ⚠️ Aspiration pneumonia (a common reason for hospitalisation in elderly Indian patients and those with stroke/dysphagia/alcohol use) is well-covered by ampicillin-sulbactam due to its excellent anaerobic activity. This is an advantage over ceftriaxone (which has limited anaerobic coverage and typically requires metronidazole addition for aspiration pneumonia).
11. Dose adjustment: Renal impairment — see Renal Adjustment.

---

• Colorectal / appendicectomy (clean-contaminated and contaminated)
• Head and neck surgery involving mucosal incision (cancer surgery, mandibulectomy)
• Upper GI / biliary surgery (open procedures, biliary tract operations)
• Gynaecological surgery (hysterectomy — especially vaginal)
• Contaminated traumatic wounds
• Bowel surgery with anticipated spillage

1. When to prefer: Provides single-agent coverage against skin flora, enteric gram-negatives, enterococci, and anaerobes — making it a versatile prophylactic choice for clean-contaminated surgeries involving the GI or gynaecological tract. Advantage over cefazolin: broader gram-negative coverage and anaerobic coverage without adding metronidazole. Advantage over cefazolin + metronidazole: also covers enterococci.
2. When NOT to use: Clean surgery where cefazolin alone is standard (cardiac surgery, orthopaedic implant surgery — where anti-staphylococcal coverage is primary concern and ampicillin-sulbactam’s broader spectrum is unnecessary). Not for prosthetic joint prophylaxis (cefazolin is standard). Not adequate where MRSA prophylaxis is specifically needed (add vancomycin).
3. NLEM India: Ampicillin ✅ NLEM.
4. ⚠️ Timing and re-dosing are critical:
   • Ampicillin-sulbactam has a shorter half-life (~1–1.5 hours) than cefazolin (~1.8–2 hours). Therefore, intraoperative re-dosing is required at 2-hour intervals for prolonged procedures (compared to 4-hour re-dosing intervals for cefazolin). Failure to re-dose is a common cause of prophylaxis failure.
   • ⚠️ For IV push administration (over 10–15 minutes), start injection ~30 minutes before incision. For IV infusion (over 15–30 minutes), start infusion ~45–60 minutes before incision.
5. ⛔ Prolonged prophylaxis error: Continuing prophylactic antibiotics for 3–7 days post-surgery is a widespread practice error in Indian surgical wards. Evidence consistently shows that prophylaxis beyond 24 hours does NOT reduce SSI rates and increases AMR, CDI risk, and cost. Active antimicrobial stewardship intervention is needed.
6. Indian guideline: API Textbook (Surgical Infections chapter); AIIMS Surgical Prophylaxis Protocol; NCDC Infection Control Guidelines.

---

1. When to prefer: Ampicillin-sulbactam is appropriate for bone and joint infections caused by susceptible organisms — particularly when polymicrobial infection or enterococcal involvement is suspected (e.g., vertebral osteomyelitis, diabetic foot osteomyelitis). Culture data is essential.
2. When NOT to use: ⛔ Not for MRSA osteomyelitis, not for Pseudomonas bone infections, not as empiric first-line without culture data.
3. Specialist initiation: ⚠️ MANDATORY — orthopaedic surgeon + ID specialist/physician involvement essential. Long-duration therapy must be supervised.
4. Key evidence for oral step-down: The OVIVA trial (2019) supports oral step-down in bone and joint infections including with oral amoxicillin-clavulanate. While OVIVA did not specifically study sultamicillin, the principle of early oral switch applies. Most Indian centres step down to oral amoxicillin-clavulanate rather than sultamicillin.
5. Baseline investigations: MANDATORY: Bone/joint culture (ideally intraoperative), blood cultures, CRP, ESR, imaging (X-ray, MRI).
6. Indian guideline: API Textbook; AIIMS Orthopaedic Infection Protocol.

---

1. When to prefer: Ampicillin-sulbactam is appropriate for hospitalised cUTI/pyelonephritis when the urine culture shows a susceptible organism. Particularly useful when enterococcal UTI (E. faecalis) is confirmed or suspected — an advantage over cephalosporins which lack enterococcal activity.
2. When NOT to use: ⚠️ In Indian practice, ESBL-producing E. coli and Klebsiella account for >40–60% of complicated UTIs in many hospital settings. Ampicillin-sulbactam is unreliable as empiric therapy for cUTI in high-ESBL-prevalence settings without culture data. If used empirically, the local antibiogram must support it.
   • Always send urine culture before starting empiric therapy.
   • For severe urosepsis: prefer piperacillin-tazobactam, ceftriaxone, or carbapenems as empiric therapy pending culture results.
3. NLEM India: Ampicillin ✅ NLEM.
4. Time to response: Defervescence within 48–72 hours. If still febrile at 72 hours → repeat urine culture, renal imaging (rule out obstruction/abscess), switch antibiotic per C&S.
5. Baseline investigations: MANDATORY: Urine routine + culture-sensitivity, allergy history. RECOMMENDED: Renal function, blood cultures, renal ultrasound (if complicated/recurrent/obstructive pathology suspected).
6. Indian guideline: ICMR AMR Treatment Guidelines 2019; API Textbook.

---

• ℹ️ Ampicillin-sulbactam IV is the most commonly used parenteral antibiotic for peritonsillar abscess in Indian ENT practice.
• Combined with needle aspiration or incision and drainage of the abscess (mandatory for treatment).
• Covers: Group A Streptococcus, oral anaerobes (Fusobacterium, Prevotella, Peptostreptococcus), S. aureus (MSSA).
• Step-down to oral amoxicillin-clavulanate after drainage + clinical improvement.

• ⛔ Airway emergency — secure airway first (anaesthesia/ENT involvement mandatory).
• Ampicillin-sulbactam IV 3 g q6h provides excellent coverage against typical oral flora (streptococci, anaerobes). Often combined with metronidazole 500 mg IV q8h for enhanced anaerobic coverage in severe cases, or clindamycin may be used as an alternative/addition.
• Surgical drainage mandatory for established abscess.

• Similar approach to peritonsillar abscess. ENT/surgical involvement mandatory.

1. NLEM India: Ampicillin ✅ NLEM.
2. Specialist initiation: ENT surgeon mandatory for all deep neck space infections.
3. Time to response: 48–72 hours after drainage + IV antibiotics.
4. Treatment failure: CT neck with contrast if not responding — assess for undrained collection, extension to mediastinum (descending necrotising mediastinitis — life-threatening), or Lemierre syndrome (internal jugular vein thrombophlebitis — Fusobacterium necrophorum).
5. Indian guideline: API Textbook (ENT Infections); AIIMS ENT Protocol.

---

1. When to prefer: 💡 Ampicillin-sulbactam is an excellent choice for aspiration pneumonia and lung abscess due to its combined aerobic + anaerobic coverage. Common pathogens: oral streptococci, anaerobes (Bacteroides, Fusobacterium, Peptostreptococcus), occasionally gram-negatives. Aspiration pneumonia is extremely common in Indian hospitals — seen in elderly patients with stroke/dysphagia, alcohol-use disorder, seizures, post-anaesthesia, ICU ventilated patients. The anaerobic coverage of ampicillin-sulbactam is a significant advantage over ceftriaxone monotherapy for this indication.
2. When NOT to use: If ventilator-associated pneumonia (VAP) with nosocomial organisms suspected — need broader coverage (piperacillin-tazobactam, carbapenems). If MRSA aspiration pneumonia suspected — add vancomycin/linezolid.
3. NLEM India: Ampicillin ✅ NLEM.
4. Baseline investigations: Chest X-ray/CT, sputum culture (may be contaminated with oral flora — interpret cautiously). Blood cultures. Bronchoscopy with BAL for lung abscess if feasible.
5. Key safety note: Lung abscess requires prolonged therapy (weeks). Monitor LFTs periodically during long courses. Chest imaging every 2–4 weeks to document cavity resolution.
6. Indian guideline: API Textbook (Pneumonia/Lung Abscess chapter).

---

---

• Ampicillin-Sulbactam 3 g IV q6h = 4 g sulbactam/day
• PLUS Sulbactam (standalone) 1.25 g IV q6h = 5 g additional sulbactam/day
• Total sulbactam = 9 g/day
• Alternatively: Sulbactam (standalone) 3 g IV q8h = 9 g/day (without ampicillin — some protocols use this approach)

• ⚠️ Specialist only — ID specialist, intensivist, and clinical microbiologist involvement mandatory. Not for initiation by general physicians.
• ⚠️ Always culture-guided. MIC of sulbactam against the specific A. baumannii isolate should guide dosing. Sulbactam MIC ≤4 mg/L: standard-dose sulbactam may suffice. MIC 8–16 mg/L: high-dose sulbactam (6–9 g/day) needed. MIC ≥32 mg/L: sulbactam unlikely to be effective.
• Renal dose adjustment applies even to high-dose regimens — see Renal Adjustment section.
• Evidence basis:Moderate — Multiple observational studies, meta-analyses (Defined Daily Dose studies, Betrosian et al., Chu et al. meta-analysis). IDSA 2024 Guidelines for treatment of A. baumannii now recommend high-dose sulbactam-based regimens (with combination) as a treatment option. Widely adopted in Indian ICU practice per AIIMS, CMC Vellore, and PGIMER protocols.
• Indian guideline: AIIMS ICU Antibiotic Protocol for MDR/XDR Acinetobacter; ICMR AMR Guideline (supportive); Indian Society of Critical Care Medicine (ISCCM) position statements.

---

• ⚠️ Specialist only — cardiologist + ID specialist. Endocarditis is a complex, high-mortality infection requiring prolonged IV therapy and close monitoring.
• The ampicillin + ceftriaxone “double beta-lactam” regimen has been validated in the RCT by Fernández-Hidalgo et al. (2013) and is now preferred over ampicillin + gentamicin in many centres (avoids aminoglycoside toxicity). AIIMS cardiology and ID departments use both regimens.
• ⛔ Does NOT apply to E. faecium endocarditis — E. faecium is inherently resistant to ampicillin. Requires vancomycin ± gentamicin, or linezolid/daptomycin.
• Evidence basis:Strong — AHA/IDSA Endocarditis Guidelines; European Heart Journal IE Guidelines; RCT data for double beta-lactam strategy. Widely adopted in Indian cardiology and ID practice.
• Indian guideline: API Textbook (Endocarditis chapter); AIIMS Endocarditis Protocol; Cardiological Society of India (CSI) recommendations.

---

• In many Indian secondary-care hospitals, ampicillin-sulbactam is used as a first-line empiric IV antibiotic for a range of moderate community-acquired infections (pneumonia, UTI, intra-abdominal, SSTI) because:
  • Single agent providing broad aerobic + anaerobic coverage
  • Covers enterococci (unlike cephalosporins)
  • No need for additional metronidazole in most mixed infections
  • Available as a reasonably affordable generic
  • Does not require aminoglycoside monitoring
• ℹ️ This “universal empiric” use is common practice but should be guided by local antibiograms. In areas with high ESBL prevalence, empiric ampicillin-sulbactam may be suboptimal for gram-negative infections.
• Evidence basis:Moderate — supported by observational data and Indian hospital protocols, though no specific RCTs comparing “universal empiric ampicillin-sulbactam” to alternatives in Indian secondary care.

---

PAEDIATRIC DOSING (Specialist Only)

---

• Safety monitoring: Monitor for diarrhoea (less common than with amoxicillin-clavulanate, as parenteral administration bypasses GI tract), allergic reactions (rash, urticaria, anaphylaxis), injection-site reactions (phlebitis for IV, pain for IM).
• Minimum age: Used from the neonatal period onwards (see separate neonatal section below). Commonly prescribed from birth under specialist supervision.
• Formulation suitability:
  • IV/IM vials (750 mg, 1.5 g) are available and suitable for paediatric use — reconstituted to appropriate volume for weight-based dosing.
  • Oral sultamicillin suspension availability in India is limited (see Formulations section). For oral step-down in children, amoxicillin-clavulanate suspension is preferred and widely available.
  • Sultamicillin tablets (375 mg) are for older children/adolescents who can swallow tablets.
• Palatability: Not a primary concern for parenteral formulations. Sultamicillin oral suspension, where available, has acceptable palatability.
• Age-specific PK differences: Neonates — prolonged half-life (3–4 hours), extended dosing intervals. Infants and children — relatively higher clearance per kg, standard weight-based dosing adequate.
• Adolescent transition: Children ≥12 years of age OR ≥40 kg body weight → use adult dosing.

---

• Per dose maximum: Ampicillin 2 g + Sulbactam 1 g (= 3 g total) per dose
• Per day maximum: Ampicillin 8 g + Sulbactam 4 g (= 12 g total) per day
• ℹ️ Daily dose expressed as total combination: maximum 300 mg/kg/day of the combination (= 200 mg/kg/day ampicillin + 100 mg/kg/day sulbactam), not exceeding adult maximum.

---

---

• ⚠️ CRITICAL: Differentiate preseptal from orbital cellulitis (see signs — proptosis, EOM restriction, visual changes, afferent pupillary defect). Orbital cellulitis is an ophthalmic/neurosurgical emergency.
• Ampicillin-sulbactam covers typical pathogens: S. aureus (MSSA), Streptococcus spp., H. influenzae (post-Hib vaccine era — less common), anaerobes (from sinusitis extension).
• CT orbit with contrast mandatory for orbital cellulitis to assess for subperiosteal or orbital abscess.
• Ophthalmology + ENT + paediatric surgery involvement for orbital cellulitis.
• Indian guideline: IAP Guidelines; AIIMS Paediatric Ophthalmology Protocol.
• NLEM: Ampicillin ✅ NLEM.

---

• Ampicillin-sulbactam is commonly used as first-line empiric IV antibiotic for paediatric acute appendicitis (uncomplicated and complicated) in many Indian paediatric surgery centres. Provides single-agent coverage against enteric gram-negatives, enterococci, and anaerobes.
• For non-perforated, uncomplicated appendicitis treated with appendectomy: short-course (24 hours) perioperative prophylaxis with ampicillin-sulbactam is adequate — no prolonged postoperative course needed.
• For perforated/complicated appendicitis: 5–7 days postoperative course per SIS guidelines.
• Baseline: CBC, CRP, blood cultures if septic, imaging (USG/CT abdomen).
• Indian guideline: IAP Paediatric Surgery Guidelines; AIIMS Paediatric Surgery Protocol.
• NLEM: ✅.

---

• ℹ️ For hospitalised paediatric CAP, first-line per IAP and WHO guidelines is IV ampicillin alone (or IV benzylpenicillin for pneumococcal pneumonia). Ampicillin-sulbactam is used when: beta-lactamase-producing organisms are suspected (H. influenzae), aspiration component is present, or prior amoxicillin/ampicillin failure.
• For children <5 years: always consider TB in non-resolving pneumonia in India.
• Combine with macrolide (azithromycin 10 mg/kg/day OD for 5 days) if atypical pneumonia suspected (children >5 years).
• Indian guideline: IAP Guidelines on Paediatric Pneumonia; WHO Pneumonia Guidelines (adapted for India).
• NLEM: ✅.

---

• Same rationale as adult SSTIs — polymicrobial coverage, bite wounds, diabetic-equivalent infections in children (rare).
• ⚠️ Dog bites in children are very common in India — always co-administer anti-rabies prophylaxis.
• ⛔ Does NOT cover MRSA.
• NLEM: ✅.

---

• Retropharyngeal and parapharyngeal abscesses are surgical emergencies in children — most common in children <5 years. Airway compromise is the primary concern.
• Ampicillin-sulbactam IV provides excellent coverage against typical polymicrobial flora: Group A Streptococcus, S. aureus (MSSA), oral anaerobes.
• ⛔ If MRSA suspected: add clindamycin or vancomycin.
• ⚠️ Life-threatening complications: airway obstruction, mediastinitis, Lemierre syndrome, carotid artery erosion.
• Surgical drainage + ENT involvement mandatory.
• Indian guideline: IAP Infectious Disease Guidelines; AIIMS Paediatric ENT Protocol.
• NLEM: ✅.

---

• Obtain urine culture (clean-catch or catheter specimen) before starting antibiotics — MANDATORY.
• ⚠️ ESBL prevalence in paediatric urinary isolates in India is rising (>30% in some centres). Empiric ampicillin-sulbactam may be unreliable — local antibiogram should guide choice.
• Ampicillin-sulbactam provides enterococcal coverage — an advantage when Enterococcus UTI is suspected (catheter-associated, or in children with urological anomalies).
• All children with first febrile UTI: renal ultrasound recommended. DMSA/MCU per IAP Paediatric Nephrology guidelines.
• Indian guideline: IAP Guidelines for UTI in Children.
• NLEM: ✅.

---

1. ⛔ Ampicillin-sulbactam is NOT the standard first-line for empiric early-onset neonatal sepsis (EONS). The standard first-line per NNF (National Neonatology Forum) India / AIIMS Neonatal Protocol / WHO is:
   • Ampicillin (alone) + Gentamicin — for suspected EONS (onset <72 hours of life)
   • The sulbactam component is not routinely needed for the typical EONS pathogens (Group B Streptococcus, Listeria monocytogenes, E. coli — most ampicillin-susceptible or treated with aminoglycoside synergy)
2. When ampicillin-sulbactam MAY be used in neonates:
   • Late-onset neonatal sepsis (LONS) — if culture reveals a beta-lactamase-producing organism susceptible to ampicillin-sulbactam (targeted therapy)
   • Neonatal intra-abdominal infections — necrotising enterocolitis (NEC) with suspected polymicrobial infection (some protocols use ampicillin-sulbactam as part of NEC regimen)
   • Neonatal soft tissue/wound infections — where polymicrobial coverage is needed
   • Always as targeted therapy based on culture in neonates, not as empiric first-line
3. Immature renal function: Neonatal half-life is prolonged (3–4 hours). Extended dosing intervals are essential. Monitor urine output and renal function.
4. IV administration in neonates: Use slow IV injection over 10–15 minutes or short IV infusion over 15–30 minutes. Ensure accurate weight-based dose calculation — small dosing errors in neonates can be proportionally large. Use syringe pump for infusion.

---

---

• ⚠️ Airway emergency — do NOT examine the throat in a suspected epiglottitis case without preparation for emergency intubation. ENT + anaesthesia + PICU involvement mandatory.
• Ampicillin-sulbactam covers H. influenzae type b (including beta-lactamase producers), Streptococcus spp., S. aureus (MSSA) — the typical epiglottitis pathogens.
• Preferred first-line for paediatric epiglottitis in most protocols: IV ceftriaxone (better CSF penetration if concurrent meningitis suspected, and broader gram-negative coverage). Ampicillin-sulbactam is a second-line alternative or can be used when IV cephalosporins are unavailable.
• Evidence basis:Weak — case series, textbook recommendations. RCTs not feasible for this rare condition.
• NLEM: ✅ (ampicillin component).

---

• NEC is one of the most devastating neonatal GI emergencies. Standard NEC antibiotic regimen per NNF/AIIMS: Ampicillin + Gentamicin + Metronidazole (or Meropenem ± Vancomycin for severe/stage III NEC).
• Ampicillin-sulbactam may replace the ampicillin + metronidazole components of the regimen — providing both ampicillin and anaerobic coverage in a single agent (sulbactam’s beta-lactamase inhibition enhances ampicillin’s activity against intestinal anaerobes and gram-negatives).
• ⚠️ Neonatologist decision only. Not standard practice at all centres.
• Evidence basis:Weak — institutional protocols, expert opinion. No paediatric RCTs comparing ampicillin-sulbactam-based NEC regimens to standard triple therapy.
• Indian guideline: NNF Clinical Practice Guidelines (NEC Management); AIIMS Neonatal Protocol (some versions include ampicillin-sulbactam as an option).

---

• ⚠️ Oral sultamicillin is occasionally used in place of amoxicillin-clavulanate in combination with ciprofloxacin for low-risk febrile neutropenia oral step-down. However, amoxicillin-clavulanate is preferred (more widely available, better-studied, more familiar formulations).
• Evidence basis:Very weak — extrapolation from adult data, rare paediatric practice.
• Specialist only: Paediatric oncologist must supervise.

---

• Used when CSOM develops intracranial or intratemporal complications (mastoiditis, brain abscess, sigmoid sinus thrombosis, meningitis) requiring IV antibiotics.
• Provides coverage against common CSOM pathogens including anaerobes and beta-lactamase-producing organisms.
• ⚠️ Inadequate Pseudomonas coverage — add antipseudomonal agent (ceftazidime, ciprofloxacin) if Pseudomonas is isolated or suspected (common in chronic ear discharge).
• ENT + neurosurgery involvement mandatory for complicated CSOM.
• Evidence basis:Weak — expert opinion, institutional protocols.
• Indian guideline: IAP ENT Guidelines; AIIMS Paediatric ENT Protocol.

---

• Used for suppurative cervical lymphadenitis not responding to oral therapy, or when surgical drainage is required.
• Covers S. aureus (MSSA), Streptococcus pyogenes, anaerobes (dental-origin), Bartonella (limited).
• ⛔ If MRSA suspected: add clindamycin or vancomycin.
• ⚠️ India-specific: Always consider tuberculous lymphadenitis in differential — FNAC + GeneXpert before labelling as bacterial.
• Evidence basis:Weak — expert opinion, textbook.
• Indian guideline: IAP Infectious Disease Guidelines.

---

---

MISSED DOSE / DELAYED DOSE GUIDANCE

ℹ️ Ampicillin-sulbactam is predominantly a parenteral antibiotic administered in a hospital/clinical setting by nursing staff on a fixed schedule. Missed dose scenarios are more relevant for: (a) nursing staff in hospital wards, (b) outpatient parenteral antibiotic therapy (OPAT) settings, and © the oral form (sultamicillin) taken at home.

---

• IV/IM doses are administered by nursing staff on a fixed q6h schedule (e.g., 06:00, 12:00, 18:00, 00:00).
• If a dose is delayed (e.g., due to surgery, procedure, line issues, NPO status):
  • Administer as soon as possible.
  • Re-space subsequent doses to maintain the q6h interval from the delayed dose.
  • Document the delay and rescheduled times in the nursing notes.
  • If the delay is >3 hours, inform the treating physician — the dosing interval has been significantly breached.
• ⚠️ For critically ill / septic patients: Even a single missed or significantly delayed IV antibiotic dose can be clinically significant — subtherapeutic levels allow bacterial regrowth. Prioritise timely administration. If a dose is delayed >2 hours, inform the treating physician immediately for reassessment.
• ⚠️ For surgical prophylaxis: If the pre-operative dose is missed or delayed past the incision time, it should still be administered ASAP — late prophylaxis is suboptimal but still provides some benefit if given within 1–2 hours after incision. If more than 2 hours post-incision, the prophylactic window is effectively lost for that dose.

• If delayed <4 hours: administer immediately, respace subsequent doses.
• If delayed >4 hours: administer immediately, skip the next dose if it would fall within 4 hours of the delayed dose, then resume regular schedule.

---

• If remembered within 6 hours of the scheduled time: Take the missed dose immediately. Then resume the regular 12-hourly schedule from that point.
• If more than 6 hours late (i.e., the next dose is due within 6 hours): Skip the missed dose entirely. Take the next dose at its scheduled time. Do NOT double the dose.

---

• Ampicillin-sulbactam is used as a finite-duration antibiotic course, not as chronic indefinite therapy.
• If 2 or more consecutive doses are missed (parenteral or oral):
  • The antibiotic will have become sub-therapeutic — bacterial regrowth and potential resistance emergence are risks.
  • Resume at the full dose immediately — no re-titration required (antibiotics are not titrated).
  • Extend the total duration of therapy by the number of days of missed doses.
  • If the patient was on IV therapy and doses were missed due to IV access loss, re-establish access and resume promptly, or consider IM route as a bridge if clinically appropriate.
  • If the infection was clinically improving before the doses were missed, monitor closely for recurrence of symptoms (fever, worsening signs).
  • If the infection was not yet controlled, reassess the patient clinically (examine, repeat cultures if possible) before simply resuming.
• No withdrawal syndrome or rebound effect with abrupt discontinuation.
• No risk of immunogenicity (not a biologic).

---

---

RECONSTITUTION / ADMINISTRATION QUICK REFERENCE (For Nurses & Clinical Staff)

---

• Dose = 75 mg/kg × 15 kg = 1125 mg total combination per dose
• Using 1.5 g (1500 mg) vial reconstituted in 3.2 mL SWFI → approximate concentration = 375 mg/mL total
• Volume to draw = 1125 mg ÷ 375 mg/mL = 3 mL
• Dilute in 25–50 mL Normal Saline; infuse over 15–30 minutes.
• Alternatively: administer 3 mL as slow IV injection over 10–15 minutes.

• Dose = 75 mg/kg × 3 kg = 225 mg total per dose
• Using 750 mg vial reconstituted in 1.6 mL SWFI → approximate concentration = 375 mg/mL
• Volume to draw = 225 mg ÷ 375 mg/mL = 0.6 mL
• Dilute in 5–10 mL Normal Saline; infuse over 15–30 minutes using a syringe pump.
• ⚠️ Precise volume measurement is critical in neonates — use a 1 mL syringe for accuracy.

• ⛔ Ampicillin-sulbactam vials are single-use vials — they do NOT contain preservatives. Once reconstituted, the entire vial should be used for a single patient’s dose(s). Any remaining solution after drawing the required dose(s) should be discarded.
• ⛔ Do NOT re-puncture a reconstituted vial to draw doses at a later time — contamination risk.
• ⛔ In neonatal settings, always use single-dose vials (preservative-free formulations).

---

---

---

• Ampicillin-sulbactam does NOT require cold-chain storage in its dry (pre-reconstitution) form. The dry powder is stable at room temperature up to 25°C (and is generally stable up to 30°C for short periods during transport).
• After reconstitution: Preferably refrigerate if not used immediately (extends stability). However, since most doses are prepared just before administration in Indian hospitals, refrigeration is often not needed.
• ℹ️ Indian context: In areas with very high ambient temperatures (>40°C during summer), store unopened vials in the coolest available area of the ward/pharmacy (not in direct sunlight, not near windows or sterilisation equipment). Reconstitute just before use.

---

RENAL ADJUSTMENT

---

• ARC is defined as measured CrCl >130 mL/min (by 8- or 24-hour urine creatinine clearance, or estimated in young patients without pre-existing CKD).
• Common in: young adults (18–50 years), polytrauma, burns, sepsis without organ failure, neurosurgical patients, early phase of septic shock (before renal impairment sets in).
• Impact on ampicillin-sulbactam: ARC results in dramatically increased renal clearance of both components → subtherapeutic serum levels with standard dosing → risk of treatment failure, especially for organisms with higher MICs (Acinetobacter, enterococci).
• Action in ARC:
  1. Increase dosing frequency: Consider q4h–q6h dosing (e.g., ampicillin-sulbactam 3 g IV every 4 hours for severe infections in ARC patients) — AIIMS and CMC Vellore ICU protocols include this approach.
  2. Extended infusions: Each dose infused over 3–4 hours (instead of 30 minutes) to maximise %fT > MIC. This is particularly relevant for high-dose sulbactam regimens against Acinetobacter.
  3. Therapeutic drug monitoring (TDM): If available, measure serum ampicillin or sulbactam levels to confirm adequate exposure. TDM for beta-lactams in ICU is an evolving practice — limited to select Indian tertiary centres.

• Both ampicillin and sulbactam can crystallise in the urine at high concentrations, particularly in dehydrated patients or those with very low urine pH.
• Prevention: Maintain adequate hydration (urine output >0.5 mL/kg/hr in adults). Particularly important in patients with renal impairment receiving high doses.
• If crystalluria occurs (haematuria, flank pain, rising creatinine): discontinue drug, hydrate aggressively, consider alternative antibiotic. Usually reversible.

---

HEPATIC ADJUSTMENT

---

• Ampicillin undergoes minimal hepatic metabolism (~10%) and is primarily renally cleared. Hepatic impairment has minimal effect on ampicillin pharmacokinetics.
• Sulbactam undergoes minimal hepatic metabolism and is similarly primarily renally cleared. Hepatic impairment has minimal direct pharmacokinetic impact on sulbactam levels.
• Both components have low protein binding (~28% for ampicillin, ~38% for sulbactam) — therefore, the hypoalbuminaemia commonly seen in liver disease will modestly increase the free (unbound) drug fraction but this is not clinically significant given the already low binding.

1. The drug’s potential (though low) for hepatotoxicity
2. The interaction with pre-existing liver disease
3. Concurrent hepatotoxin use

---

CONTRAINDICATIONS

---

---

• Rationale: Risk of immediate (IgE-mediated) anaphylaxis (Type I hypersensitivity) — potentially fatal. Also includes history of angioedema, severe urticaria, or bronchospasm with any penicillin.
• Allergy cross-reactivity — DETAILED:

---

• Rationale: Risk of recurrence on re-exposure, potentially more severe.
• ℹ️ If the documented DILI was from amoxicillin-clavulanate (specifically attributed to clavulanate), ampicillin-sulbactam may be cautiously considered as an alternative — since sulbactam has a different hepatotoxicity profile from clavulanate. However, use with close LFT monitoring and only if no better alternative exists. This is a clinical judgement call, not a blanket contraindication.

---

• Rationale: Shared beta-lactam ring creates risk of cross-reactive anaphylaxis, though absolute cross-reactivity rates are lower than historically believed (see table above).
• Exception: If the anaphylaxis was to a specific beta-lactam with a distinctly different side chain (e.g., aztreonam), and formal allergy testing has excluded ampicillin cross-reactivity, use may be considered under specialist allergy supervision.

---

• Rationale: Ampicillin (and other antibiotics active against Salmonella Typhi) can inactivate the live attenuated oral typhoid vaccine strain, rendering vaccination ineffective.
• Action: Complete the antibiotic course and wait ≥3 days (preferably 7 days) before administering oral typhoid vaccine. Injectable typhoid vaccines (Vi polysaccharide, conjugate vaccines) are NOT affected.

---

CAUTIONS

---

---

• Risk: Aminopenicillins (ampicillin, amoxicillin) cause a characteristic diffuse maculopapular rash in 70–100% of patients with acute EBV mononucleosis. This is NOT a true IgE-mediated allergy — it is a virus-drug interaction (possibly T-cell-mediated immune response in the context of EBV-altered lymphocyte activity).
• Action: ⛔ Avoid ampicillin-sulbactam if infectious mononucleosis is suspected or confirmed (sore throat + lymphadenopathy + hepatosplenomegaly + atypical lymphocytes + positive heterophile/Monospot test). This is the historical “ampicillin rash” from which the phenomenon was first described.
• ⚠️ If a patient with undiagnosed EBV develops a rash on ampicillin: This does NOT indicate true penicillin allergy. Document clearly: “Rash in context of suspected EBV mononucleosis — NOT penicillin allergy.” Consider future allergy testing to avoid permanent mislabelling.
• ⚠️ India-specific: Young adults (15–30 years) with “tonsillitis” are frequently given empiric ampicillin/amoxicillin in outpatient settings. If they develop a widespread rash, the diagnosis of EBV mononucleosis should be considered — and the rash should NOT be automatically labelled as penicillin allergy.

---

• Risk: Both components accumulate significantly. Risk of neurotoxicity (myoclonic seizures — rare but serious), increased GI adverse effects, crystalluria.
• Monitoring: Renal function (serum creatinine, electrolytes) at baseline and periodically during therapy. Ensure adequate hydration.
• Action: Dose interval extension mandatory — see Renal Adjustment section.

---

• Risk: High-dose ampicillin (especially in renal impairment) can lower the seizure threshold — the mechanism involves GABA antagonism at high CSF concentrations of beta-lactams (a class effect). Risk is dose-dependent and primarily seen with very high IV doses or renal failure.
• Action: Use standard doses with caution. Ensure renal dose adjustment. Monitor for any change in seizure frequency. If high-dose sulbactam regimens are used (for Acinetobacter), seizure risk may increase — monitor neurological status closely in ICU.

---

• Risk: All broad-spectrum antibiotics disrupt colonic flora and increase CDI risk. Patients with prior CDI are at significantly higher risk of recurrence.
• Monitoring: Monitor for new-onset watery diarrhoea (≥3 loose stools/day), especially if bloody or with fever/abdominal pain. Test for C. difficile toxin if suspected.
• Action: Use only if clearly indicated. Keep duration as short as possible. If CDI develops: stop ampicillin-sulbactam, start specific CDI treatment (oral vancomycin 125 mg QDS × 10 days).

---

• Risk: Ampicillin (like other broad-spectrum antibiotics) can increase INR by disrupting gut flora → reduced vitamin K synthesis → potentiated anticoagulant effect. Additionally, severe infection and reduced oral intake may independently alter warfarin metabolism.
• Monitoring: Check INR within 3–5 days of starting ampicillin-sulbactam. Repeat at course completion. Adjust anticoagulant dose if INR rises above target range.
• Action: See Drug Interactions section.

---

• Risk: At high sulbactam doses (6–9 g/day), risks include: neurotoxicity (seizures, myoclonus, encephalopathy — especially in renal impairment), nephrotoxicity (rare, with very high doses), significant electrolyte disturbance (sodium load from sodium salt of sulbactam).
• Monitoring: Daily neurological assessment. Renal function every 48 hours. Electrolytes (sodium, potassium). In patients with renal impairment, consider TDM (if available) to avoid toxic accumulation.
• Action: ⚠️ Specialist only (ICU/ID). Renal dose adjustment applies to high-dose regimens as well. If seizures develop on high-dose sulbactam: reduce dose immediately, administer benzodiazepine for active seizure, evaluate renal function.

---

• Each 1.5 g vial of ampicillin-sulbactam (as sodium salts) contains approximately 115 mg sodium (~5 mEq).
• At maximum dosing (3 g q6h = 12 g/day), the daily sodium load from the drug alone is approximately ~20 mEq/day.
• Risk: In patients with heart failure (fluid overload, sodium restriction), cirrhosis with ascites, or severe hypertension, this additional sodium load may be clinically significant — especially when combined with other IV fluid sodium.
• Action: Consider the drug’s sodium content in the patient’s total daily sodium budget. Use the minimum effective dose. Monitor fluid status, daily weights, and serum sodium in sodium-restricted patients.

---

---

• Use with caution. Although ampicillin-sulbactam has a low hepatotoxicity risk (lower than amoxicillin-clavulanate), any pre-existing liver disease warrants baseline LFTs and clinical monitoring. See Hepatic Adjustment section.

---

• Antibiotics may exacerbate IBD flares or cause antibiotic-associated colitis superimposed on IBD. Monitor bowel symptoms closely. Differentiate IBD flare from CDI (test for C. difficile if new symptoms develop).

---

• Prolonged or repeated antibiotic courses can lead to overgrowth of non-susceptible organisms: oral candidiasis (common in elderly, immunocompromised, steroid users, denture wearers), vaginal candidiasis (common in women, especially postpartum), resistant gram-negative organisms (ESBL producers, Pseudomonas).
• Action: Monitor for candidiasis (oral/vaginal). Treat with topical nystatin (oral) or clotrimazole (vaginal) as needed. In hospitalised patients on prolonged therapy, surveillance cultures may detect emerging resistant organisms.

---

• ℹ️ Urine glucose testing interference: Ampicillin can cause false-positive urine glucose tests when using copper-reduction methods (e.g., Benedict’s test, Clinitest). Enzymatic glucose tests (glucose oxidase — Diastix, glucometer strips) are NOT affected.
• Action: Use enzymatic glucose testing methods in patients on ampicillin-sulbactam. Counsel diabetic patients and laboratory staff.

---

• False-positive direct Coombs test: Ampicillin can cause positive direct antiglobulin test (DAT/Coombs test), potentially interfering with crossmatching for blood transfusion. Clinically significant haemolytic anaemia is very rare.
• Interference with urinary protein estimation: High-dose ampicillin may interfere with some protein assays (sulfosalicylic acid turbidity method).
• False-positive urine glucose: As noted above (copper-reduction methods).
• Action: Alert the laboratory if the patient is on ampicillin-sulbactam before ordering these tests.

---

• Ampicillin-sulbactam crosses the placenta and is excreted in breast milk. See dedicated Pregnancy and Lactation sections (Part 4) for detailed guidance. In general: compatible with use in pregnancy and lactation when clinically indicated.

---

• IM injection of ampicillin-sulbactam is painful. Reconstitution with 0.5% lidocaine (lignocaine) solution reduces pain significantly and is standard practice (see Administration section).
• Monitor injection site for: sterile abscess, induration, persistent pain. Rotate sites if repeated IM doses are required.
• ⛔ Do NOT inject IM into areas with compromised blood supply (e.g., irradiated tissue, severe peripheral vascular disease) — poor absorption risk.

---

• Risk of superinfection (candidiasis, resistant organisms, CDI) increases with duration.
• Risk of drug-related haematological effects (reversible neutropenia, thrombocytopenia, eosinophilia) increases with prolonged high-dose therapy.
• Monitoring: CBC with differential every 1–2 weeks during prolonged courses. LFTs every 2–4 weeks. Clinical assessment for superinfection at each review.
• Document the clinical rationale for extending therapy beyond 14 days.

---

• Delayed maculopapular rash occurs in ~3–7% of patients (similar to ampicillin alone). Most are non-severe and self-limiting.
• ⚠️ Distinguish from:
  • Severe drug eruptions (SJS/TEN) — blistering, mucosal involvement → STOP IMMEDIATELY
  • DRESS — fever + rash + eosinophilia + organ involvement → STOP IMMEDIATELY
  • Serum sickness-like reaction — fever + joint pain + rash after 7–21 days → STOP, supportive care
  • EBV-associated rash — in context of mononucleosis (see above) → NOT true allergy
• If mild maculopapular rash without systemic features: may cautiously continue if the infection is serious and no alternative is available — but monitor closely and document the decision. Discontinue if rash progresses.

---

PREGNANCY

---

• Mother: Standard adverse effect monitoring. Renal function (pregnancy physiologically increases GFR — note for dose adequacy). Monitor for vaginal candidiasis (increased risk in pregnancy + antibiotics). LFTs if prolonged course.
• Fetus/Neonate: No specific fetal monitoring required for standard courses. For chorioamnionitis treatment: standard fetal heart rate monitoring per obstetric protocol. Post-delivery: observe neonate for oral candidiasis, loose stools, and signs of sensitisation (rare).

• Not applicable — ampicillin-sulbactam is used as acute/short-course therapy, not chronic medication. No pre-conception washout period required.
• No requirement for contraception during use.
• No pregnancy prevention programme applicable.

• No specific pregnancy exposure registry exists for ampicillin-sulbactam in India. If adverse pregnancy outcomes are suspected to be drug-related, report through PvPI (Pharmacovigilance Programme of India).

---

LACTATION

---

• Loose stools or diarrhoea (most common — usually mild)
• Nappy/diaper rash (secondary to altered stool)
• Oral thrush (white patches in mouth) — treat with nystatin oral drops if it occurs
• Skin rash or signs of allergic reaction (very rare — if noticed, stop maternal antibiotic and seek medical attention)
• Feeding difficulties, irritability, or excessive drowsiness (very rare)

• ℹ️ For IV/IM administration (hospital setting): The mother is typically receiving doses on a fixed schedule. Breastfeeding may continue at any time relative to the IV/IM dose. The RID is sufficiently low that timing relative to dose is not critical.
• ℹ️ For oral sultamicillin (if used): Optional timing strategy — take the dose immediately after completing a breastfeed to allow serum levels to decline before the next feed. However, this is NOT mandatory given the very low infant exposure.

• Ampicillin alone (IV/IM) — compatible with breastfeeding
• Oral amoxicillin — compatible, most widely used antibiotic during lactation
• Oral amoxicillin-clavulanate — compatible, widely used
• Cephalexin — compatible
• Erythromycin — compatible (but more maternal GI side effects)

---

ELDERLY

---

• Review and discontinue promptly when the clinical indication is fulfilled. In elderly hospitalised patients, IV antibiotics are sometimes continued beyond medical necessity.
• IV-to-oral step-down: Switch to oral therapy (amoxicillin-clavulanate) as soon as the patient is: (a) clinically improving, (b) afebrile ≥48 hours, © tolerating oral intake, (d) with functioning GI tract. Early step-down reduces IV line–related complications (phlebitis, line infections) and facilitates earlier discharge — particularly important for elderly patients at risk of hospital-acquired complications (delirium, falls, nosocomial infections, deconditioning).

---

MAJOR DRUG INTERACTIONS

---

---

MODERATE DRUG INTERACTIONS

---

---

COMMON ADVERSE EFFECTS

---

---

SERIOUS ADVERSE EFFECTS

---

---

---

---

MONITORING REQUIREMENTS

---

---

---

• For standard short courses (5–10 days) in otherwise healthy patients: no ongoing monitoring needed after course completion.
• For prolonged courses: continue monitoring haematology and LFTs for 2–4 weeks after completing therapy (to capture delayed-onset adverse effects).
• Post-treatment culture follow-up as clinically indicated (e.g., repeat urine culture post-UTI treatment, repeat blood cultures for endocarditis/bacteraemia clearance documentation).

---

PATIENT COUNSELLING

---

---

---

• “The injection will be given by the nurse every 6 hours (4 times a day) — usually at fixed times like 6 AM, 12 noon, 6 PM, and 12 midnight.”
• “The injection into the vein (IV) takes 15–30 minutes through a drip or slow push. You may feel some warmth or mild stinging at the injection site — this is normal.”
• “If the injection is given into a muscle (IM), it may be painful at the site. The nurse may mix the medicine with a numbing agent (lidocaine) to reduce pain.”
• “You may notice the IV site becoming red or swollen (phlebitis) — tell the nurse immediately so they can change the IV to a different spot.”

• “Swallow the tablet whole with a full glass of water.”
• “You can take it with or without food. Taking it with food may help if you feel nauseous.”
• “Take it every 12 hours at the same times each day (e.g., 8 AM and 8 PM).”

---

---

• Pain at the injection site (if given as a muscle injection) — this is the most common side effect. Applying a warm cloth to the area may help.
• Redness or swelling at the IV drip site — tell the nurse so they can change the spot.
• Loose motions (mild diarrhoea) — drink plenty of water and eat curd (dahi/yoghurt). This is usually mild.
• Mild nausea or stomach upset — usually settles within a day or two.
• Mild skin rash — inform your doctor, but don’t stop the medicine without asking first.
• White patches in the mouth (thrush) or vaginal itching — tell your doctor; simple treatment is available."

---

• Skin rash with blisters, peeling, or sores in the mouth, eyes, or private parts
• Swelling of face, lips, tongue, or throat; difficulty breathing or swallowing
• Severe watery or bloody diarrhoea with stomach cramps and fever — even if this starts AFTER you have finished the antibiotic course
• Yellow colour of eyes or skin, very dark urine
• Unusual bruising or bleeding — especially if you are on blood-thinning medicines
• Very little or no urine output, blood in urine, or back pain
• Muscle twitching, jerking, or seizures (fits)
• Fever that returns after initially improving, or new high fever — this may mean the infection is not responding or a new problem has developed"

---

• Do NOT stop the antibiotic early — even if you feel better. The full course must be completed as prescribed by your doctor. Stopping early can cause the infection to return and the germs to become resistant.
• Alcohol: No absolute ban, but alcohol can worsen nausea and dehydration. Best to avoid during treatment for infection.
• Do NOT share your medicine with others.
• Inform your doctor about ALL other medicines you are taking — especially blood thinners (warfarin/Acitrom), gout medicines (allopurinol), and medicines taken after organ transplant.

---

---

---

• If your symptoms do not improve after 3 days of treatment
• If symptoms return after finishing the course
• For any blood tests your doctor has asked for
• If you develop any warning signs mentioned above — even weeks after the antibiotic course is finished"

---

---

• Make sure the patient gets all doses on time — remind the nurse if a dose seems delayed.
• Report to the nurse immediately if you notice: skin rash, swelling of face/lips, severe diarrhoea, yellow eyes, confusion, or seizures.
• Ensure the patient drinks enough water (unless the doctor has restricted fluids).
• Ask the doctor daily whether the patient can be switched from injection to tablets — this may allow earlier discharge.

• The injection may be painful — comfort your child. Ask the nurse about using numbing medicine in the injection.
• Watch for: skin rash, diarrhoea (especially bloody), vomiting, oral thrush (white patches in mouth), fever not improving.
• Complete the full course of medicine as instructed.
• If your child is switched to oral medicine (amoxicillin-clavulanate syrup) at discharge, use ONLY the measuring cup/syringe provided — not a household spoon."

---

---

BRANDS AVAILABLE IN INDIA

---

---

---

PRICE RANGE (INR)

---

1. Ampicillin-sulbactam injection is significantly cheaper than piperacillin-tazobactam and carbapenems — making it a cost-effective empiric choice for community-acquired infections where its spectrum is adequate.
2. Early IV-to-oral step-down reduces costs dramatically — switching from IV ampicillin-sulbactam (₹160–720/day for 1.5 g q6h) to oral amoxicillin-clavulanate (₹30–90/day) represents a 5–10× cost reduction per day plus savings on IV consumables, nursing time, and bed-day costs.
3. For oral step-down, amoxicillin-clavulanate is cheaper and more widely available than sultamicillin in India. Prescribers should use amoxicillin-clavulanate for oral step-down unless there is a specific reason to prefer sultamicillin.

---

CLINICAL PEARLS

---

---

---

---

---

---

---

VERSION

---

REFERENCES

---

1. CDSCO Product Insert — Magnex (Ampicillin Sodium + Sulbactam Sodium for Injection), Pfizer Ltd, India. Referenced for formulation details, approved indications, and Indian-specific labelling.
2. CDSCO Product Insert — Ampisyn-SB (Ampicillin + Sulbactam), Cipla Ltd, India. Referenced for reconstitution, stability, and administration details.
3. Indian Pharmacopoeia (IP) 2022, Indian Pharmacopoeia Commission, Ghaziabad. Monograph on Ampicillin Sodium and Sulbactam Sodium for Injection. Monograph on Sultamicillin Tosylate Tablets.
4. National List of Essential Medicines (NLEM) India, 2022. Ministry of Health and Family Welfare, Government of India. Section: Anti-infective Medicines — Antibacterials (Beta-lactam medicines). Confirms inclusion of Ampicillin Injection (250 mg, 500 mg). Sulbactam combination usage noted.
5. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th Edition (2023). Chapter: Penicillins, Cephalosporins, and Other Beta-Lactam Antibiotics. Chapter: Beta-Lactamase Inhibitors. Used for pharmacology depth — sulbactam’s intrinsic anti-Acinetobacter mechanism (PBP1/PBP3 binding), pharmacokinetic data, drug transporter profiles, sultamicillin prodrug hydrolysis.
6. Harrison’s Principles of Internal Medicine, 21st Edition (2022). Chapters on: Treatment of Bacterial Infections; Community-Acquired Pneumonia; Aspiration Pneumonia and Lung Abscess; Intra-Abdominal Infections; Skin and Soft Tissue Infections; Osteomyelitis; Pelvic Inflammatory Disease; Infective Endocarditis; Infections Due to Acinetobacter Species.

1. API (Association of Physicians of India) Textbook of Medicine, 11th Edition (2019). Chapters on: Antimicrobial Therapy; Community-Acquired Pneumonia; Aspiration Pneumonia; Intra-Abdominal Infections; Obstetric and Gynaecological Infections; Skin and Soft Tissue Infections; Bone and Joint Infections; Deep Neck Space Infections; Endocarditis.
2. ICMR Treatment Guidelines for Antimicrobial Use in Common Syndromes, 2nd Edition (2019). Indian Council of Medical Research, New Delhi. Referenced for empiric antibiotic recommendations, CAP management, UTI management, surgical prophylaxis, and Acinetobacter treatment approaches.
3. AIIMS Empiric Antibiotic Guidelines / Antibiotic Policy. All India Institute of Medical Sciences, New Delhi. Referenced for hospital-level prescribing protocols, surgical prophylaxis re-dosing intervals, ICU antibiotic protocols for MDR/XDR Acinetobacter, obstetric infection protocols, and IV-to-oral step-down criteria.
4. IAP (Indian Academy of Pediatrics) Guidelines. Referenced: IAP Guidelines on Paediatric Pneumonia; IAP Guidelines on UTI in Children; IAP Infectious Disease Chapter — management of periorbital/orbital cellulitis, deep neck space infections.
5. FOGSI (Federation of Obstetric and Gynaecological Societies of India) Guidelines. Referenced for obstetric infection management — chorioamnionitis, post-partum endometritis, PID.
6. NNF (National Neonatology Forum) India — Clinical Practice Guidelines. Referenced for neonatal sepsis regimens and NEC antibiotic management.
7. ISCCM (Indian Society of Critical Care Medicine) Position Statements / Consensus Documents. Referenced for ICU antimicrobial management of MDR/XDR Acinetobacter and augmented renal clearance guidance.

1. IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections (2024 Update). Infectious Diseases Society of America. Referenced for high-dose sulbactam-based treatment of carbapenem-resistant Acinetobacter baumannii (CRAB). Includes sulbactam-durlobactam data and high-dose ampicillin-sulbactam regimen recommendations.
2. OVIVA Trial: Li HK, Rombach I, Zamber R, et al. “Oral versus Intravenous Antibiotics for Bone and Joint Infection.” N Engl J Med. 2019;380(5):425–436. Referenced for oral step-down bone and joint infection evidence.
3. Fernández-Hidalgo N, Almirante B, Gavaldà J, et al. “Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating Enterococcus faecalis infective endocarditis.” Clin Infect Dis. 2013;56(9):1261–1268. Referenced for double beta-lactam strategy for enterococcal endocarditis.
4. ORACLE-I Trial: Kenyon SL et al. “Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial.” Lancet. 2001;357:979–988. (And 7-year follow-up: Lancet. 2008;372:1310–1318). Referenced for PPROM antibiotic caution — extrapolation of clavulanate data to sulbactam discussion.
5. Chu H, Zhao L, Wang M, et al. “Sulbactam-based therapy for Acinetobacter baumannii infection: a systematic review and meta-analysis.” Braz J Infect Dis. 2013;17(4):389–394. Referenced for high-dose sulbactam evidence synthesis.

1. National Rabies Control Programme, Government of India. Referenced for bite wound management context.
2. GOLD (Global Initiative for Chronic Obstructive Lung Disease) Report 2024. Supportive reference for AECOPD context.
3. Surgical Infections Society (SIS) — Revised Guidelines on the Management of Intra-Abdominal Infection (2017). Referenced for IAI antibiotic duration and source-control-based treatment approach.
4. AHA/IDSA Guidelines for Infective Endocarditis (2015, with 2023 focused update). Referenced for enterococcal endocarditis treatment regimens.
5. NPPA (National Pharmaceutical Pricing Authority) / DPCO Price Ceiling Data. Referenced for pricing and price-control status.
6. Jan Aushadhi (PMBJP) Product Catalogue, 2024–2025. Referenced for generic brand availability and pricing at Jan Aushadhi Kendras.
7. CDSCO NSQ (Not of Standard Quality) Alerts Database — www.cdsco.gov.in. Checked for quality alerts on ampicillin-sulbactam brands.
8. PvPI (Pharmacovigilance Programme of India). Referenced for adverse drug reaction reporting protocol.

---